SG&A Expense Trends: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding financial trends is crucial. Over the past decade, Neurocrine Biosciences, Inc. and Bio-Techne Corporation have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Neurocrine's SG&A expenses skyrocketed by nearly 4,800%, reflecting its aggressive growth strategy. In contrast, Bio-Techne's expenses increased by approximately 550%, indicating a more measured expansion.

A Closer Look at the Numbers

In 2014, Bio-Techne's SG&A expenses were about three times higher than Neurocrine's. However, by 2023, Neurocrine had surpassed Bio-Techne, with expenses reaching nearly 2.3 times that of its competitor. This shift highlights Neurocrine's rapid scaling efforts. Notably, data for 2024 is incomplete, with Neurocrine's figures missing, suggesting potential reporting delays or strategic changes.

These trends offer valuable insights into the operational strategies of these biotech leaders, providing investors and analysts with a clearer picture of their financial health.